- Gilead Sciences, Inc. GILD reports Q3 EPS of $2.75, missing the Street’s consensus by $0.11.
- Revenue of $7.5 billion, down 9.5 percent year-over-year, managed to beat estimates by $50 million.
- Full year net product sales guidance of $29.5 billion to $30.5 billion was reiterated.
- Shares were trading down 1.4 percent to $73.25 after hours.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in